OncoGenex Pharmaceuticals Company Profile (NASDAQ:OGXI)

Analyst Ratings

Consensus Ratings for OncoGenex Pharmaceuticals (NASDAQ:OGXI) (?)
Ratings Breakdown: 2 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $3.33 (261.93% upside)

Analysts' Ratings History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Show:
DateFirmActionRatingPrice TargetActions
1/22/2016Needham & Company LLCLower Price TargetBuy$6.00 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/21/2016Royal Bank Of CanadaLower Price TargetSector Perform$1.60 -> $1.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/2/2015Stifel NicolausDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/24/2015William BlairReiterated RatingBuy$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016Q216($0.22)$1.17 millionN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2016Q116($0.12)($0.12)$4.09 million$2.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q4($0.15)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q3($0.17)($0.16)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q2$0.34($0.26)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.34)($0.20)$4.66 million$1.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2015Q414($0.30)($0.27)$4.30 million$5.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014($0.38)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014($0.55)($0.47)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2014($0.50)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2014Q113($0.66)($0.45)$10.20 million$8.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.49)($0.40)$4.52 million$6.57 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.07)($0.07)($0.07)
Q2 20161($0.27)($0.27)($0.27)
Q3 20161($0.28)($0.28)($0.28)
Q4 20161($0.28)($0.28)($0.28)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/13/2016Cindy JacobsCMOSell1,437$1.03$1,480.11View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2016Scott Daniel CormackCEOSell4,856$1.03$5,001.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Cindy JacobsCMOSell3,254$0.83$2,700.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016John BencichCFOSell834$0.83$692.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Scott Daniel CormackCEOSell12,033$0.83$9,987.39View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015John BencichCFOSell1,427$2.76$3,938.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015Cindy JacobsCMOSell1,408$2.69$3,787.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015Scott Daniel CormackCEOSell4,571$2.69$12,295.99View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2015Cindy JacobsCMOSell2,092$1.88$3,932.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2015Scott Daniel CormackCEOSell7,543$1.88$14,180.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Cindy JacobsCMOSell5,650$3.17$17,910.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Scott Daniel CormackCEOSell18,341$3.17$58,140.97View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2014Cindy JacobsCMOSell1,250$12.25$15,312.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2014Scott Daniel CormackCEOSell4,634$12.25$56,766.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2013Cindy JacobsCMOSell1,364$8.68$11,839.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2013Scott Daniel CormackCEOSell3,112$8.68$27,012.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/12/2013Scott Daniel CormackCEOSell2,134$11.90$25,394.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2012Jack GoldsteinDirectorBuy1,000$14.38$14,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
DateHeadline
07/23/16 09:34 AMEquity Roundup: Stock Performance Focus on OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) - Press Telegraph
07/22/16 02:18 PMETF’s with exposure to OncoGenex Pharmaceuticals, Inc. : July 22, 2016 -
07/22/16 08:35 AMOncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/22/16 08:35 AMOncogenex Pharmaceuticals Incorporated (NASDAQ:OGXI) Short Interest Decreased By 4.48% - Consumer Eagle
07/22/16 08:35 AMOncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) Stock Technicals Hit Extreme Weakness - CML News
07/21/16 03:01 PMOncoGenex to Report Second Quarter 2016 Financial Results on August 4, 2016 - [CNW Group] - OncoGenex to Report Second Quarter 2016 Financial Results on August 4, 2016
07/19/16 05:43 PMWere Analysts Bearish OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) This Week? - Consumer Eagle
07/19/16 05:43 PMOncoGenex Pharmaceuticals, Inc. (NasdaqCM:OGXI) Fundamental Star Rating Report - CML News
07/18/16 11:02 AMOncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) Wall Street Analyst Recommendation Outlook - TGP
07/17/16 05:00 PMShares Moving Down on the Week: OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) - Engelwood Daily
07/15/16 10:31 AMOncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/13/16 08:34 AMWall Street Ratings and Target Price Views on OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) - Telanagana Press
07/12/16 09:55 AMHow Analysts Feel About OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI)? - Consumer Eagle
07/09/16 08:48 AMEarnings Surprise in Focus: OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) - Investor Newswire
07/07/16 08:33 AMCan OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) Improve on the Earnings Front? - Engelwood Daily
07/06/16 10:15 AMBroker Outlook For The Week Ahead OncoGenex Pharmaceuticals Inc. (OGXI) - Fiscal Standard
06/30/16 11:25 AMETF’s with exposure to OncoGenex Pharmaceuticals, Inc. : June 30, 2016 -
06/29/16 05:31 PMOncogenex Pharmaceuticals Incorporated (NASDAQ:OGXI) Shorts Decreased by 16.46% After Short Covering - Engelwood Daily
06/29/16 05:31 PMCovering the Bases on OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI): Where is the Stock Going? - Press Telegraph
06/28/16 02:52 PMForget Valeant, Invest in These Attractive Drug Stocks Instead -
06/27/16 05:36 PMNext Weeks Broker Price Targets For OncoGenex Pharmaceuticals Inc. (OGXI) - Fiscal Standard
06/24/16 05:36 PMNew Broker Ratings For OncoGenex Pharmaceuticals Inc. (OGXI) - FTSE News
06/23/16 08:18 AMOncoGenex Pharmaceuticals Inc. (OGXI) Current Analyst Ratings - Fiscal Standard
06/20/16 07:01 AMONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events -
06/07/16 05:51 PMTwo Stocks within Traders Observation: Minerva Neurosciences, Inc (NASDAQ:NERV) , OncoGenex Pharmaceuticals ... - Street Updates
06/06/16 05:32 PMOncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) Earns Consensus Hold Rating - iStreetWire
06/06/16 09:19 AMOncoGenex Pharmaceuticals Inc. (OGXI) Broker Price Targets For The Coming Week - Share Trading News
06/03/16 06:06 PMBiotech Stocks within Assessment: MannKind Corporation (NASDAQ:MNKD) , OncoGenex Pharmaceuticals Inc ... - Is stories
06/03/16 02:32 PMETF’s with exposure to OncoGenex Pharmaceuticals, Inc. : June 3, 2016 -
06/02/16 05:59 PMBuy, Sell Or Hold Rating For OncoGenex Pharmaceuticals Inc. (OGXI)? - Share Trading News - Buy, Sell Or Hold Rating For OncoGenex Pharmaceuticals Inc. (OGXI)?Share Trading NewsOncoGenex Pharmaceuticals Inc. has a 50 day moving average of 0.93 and a 200 day moving average of 1.00. The stock's market capitalization is 31.41M, it has a 52-week low of 0.46 and a 52-week high of 4.10. The share price of the company (OGXI) was ...Tracking Unusual Volume for: OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI)Franklin IndependentOncoGenex Pharmaceuticals Inc. (OGXI) Analyst ReviewRisers & FallersTop Stock in Session: OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI)The PostNews Tribuneall 5 news articles »
06/01/16 05:06 AMONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters -
05/27/16 10:38 PMOncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) Closes At $1.0000 - Investor Newswire - OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) Closes At $1.0000Investor NewswireThe technical analysis of OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) stock highlights the stock is $0.0607 points away +6.7064% from its 50-day MA of $0.9044. It is $-0.0849 or -8.0857% away $1.0500, the 200-day Moving Average (MA) of stock.and more »
05/25/16 05:14 PMOncogenex Pharmaceuticals Incorporated (NASDAQ:OGXI) Shorted Shares Increased By 35.48% - Wall Street Hints and News - Oncogenex Pharmaceuticals Incorporated (NASDAQ:OGXI) Shorted Shares Increased By 35.48%Wall Street Hints and NewsThe short interest to Oncogenex Pharmaceuticals Incorporated's float is 3.92%. The stock is down 1.60% or $0.016 after the news, hitting $0.955 per share. About 639,680 shares traded hands. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) has declined ...
05/23/16 05:17 PMTraders Are Watching: Kornit Digital Ltd. (NASDAQ:KRNT), OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI ... - KC Register - Traders Are Watching: Kornit Digital Ltd. (NASDAQ:KRNT), OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI ...KC RegisterOncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced its first quarter 2016 financial results and provided a summary of anticipated milestones. Revenue for the three months ended March 31, 2016 and 2015 was $2.9 million and $1.4 million, ...and more »
05/21/16 08:37 AMRevenue Update on OncoGenex Pharmaceuticals Inc(NASDAQ:OGXI) - Trade Calls - Revenue Update on OncoGenex Pharmaceuticals Inc(NASDAQ:OGXI)Trade CallsOncoGenex Pharmaceuticals Inc(NASDAQ:OGXI) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 12, 2016. Company reported revenue of $2.94M. Analysts estimated a revenue of $4.09M.Oncogenex Pharmaceuticals Incorporated (NASDAQ:OGXI) Shorted Shares Increased 35.48% After Market SellingWall Street Hints and Newsall 3 news articles »
05/20/16 10:21 PMOncogenex Pharmaceuticals Incorporated (NASDAQ:OGXI) Shorted Shares Increased 35.48% After Market Selling - Wall Street Hints and News - Oncogenex Pharmaceuticals Incorporated (NASDAQ:OGXI) Shorted Shares Increased 35.48% After Market SellingWall Street Hints and NewsThe short interest to Oncogenex Pharmaceuticals Incorporated's float is 3.92%. The stock decreased 0.56% or $0.005 on May 20, hitting $0.89. About 147,286 shares traded hands. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) has declined 56.94% ...
05/19/16 06:48 PMETF’s with exposure to OncoGenex Pharmaceuticals, Inc. : May 19, 2016 -
05/17/16 02:34 PMOncoGenex Pharmaceuticals, Inc. :OGXI-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/13/16 05:32 PMLatest Analyst Ratings For OncoGenex Pharmaceuticals Inc. (OGXI) - Share Trading News - Latest Analyst Ratings For OncoGenex Pharmaceuticals Inc. (OGXI)Share Trading NewsOncoGenex Pharmaceuticals Inc. has a 50 day moving average of 0.85 and a 200 day moving average of 1.14. The stock's market capitalization is 24.74M, it has a 52-week low of 0.46 and a 52-week high of 4.10. The share price of the company (OGXI) was ...OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2016PR Newswire (press release)OncoGenex Pharmaceuticals' (OGXI) CEO Scott Cormack on Q1 2016 Results - Earnings Call TranscriptSeeking Alphaall 3 news articles »
05/13/16 03:52 AMOncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2016 - PR Newswire (press release) - OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2016PR Newswire (press release)Based on current expectations, OncoGenex believes that its cash, cash equivalents, and short-term investments will be sufficient to fund its currently planned operations into the third quarter of 2017. Depending on timing of enrollment or event-driven ...OncoGenex Pharmaceuticals' (OGXI) CEO Scott Cormack on Q1 2016 Results - Earnings Call TranscriptSeeking Alphaall 2 news articles »
05/12/16 06:18 PMEdited Transcript of OGXI earnings conference call or presentation 12-May-16 8:30pm GMT -
05/12/16 04:27 PMOncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2016 - [at noodls] - May 12, 2016 BOTHELL, Wash. and VANCOUVER, British Columbia, May 12, 2016 /CNW/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its first quarter 2016 financial results and provided a ...
05/12/16 03:12 PM4:12 pm OncoGenex Pharma reports Q1 EPS of ($0.12) vs ($0.12) Capital IQ Consensus Estimate; revs 111.1% y/y to $2.9 mln vs $4.1 mln Captial IQ Consensus Estimate. -
05/12/16 06:07 AMQ1 2016 OncoGenex Pharmaceuticals Inc Earnings Release - After Market Close -
05/10/16 05:33 PMConsensus Rating Review for OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) - B.O.D.Y Confidential - Consensus Rating Review for OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1 on shares of OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, ...and more »
05/10/16 05:33 PMBuy Recommendations Count For OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) At 0 - Stocks Daily - NewsWay 21Buy Recommendations Count For OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) At 0Stocks DailyZacks rating methodology assigns scores to companies on a simplified 1-5 scale. A score towards the 1-2 band indicates a Buy call, 3 score implies a Hold while a rating of 4 or 5 denotes Sell call. Each brokerage group has its own way of assigning ...OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) Company Ratings ViewThe Postall 63 news articles »
05/09/16 05:27 PMHave a look at Price Moves: OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) , Sage Therapeutics, Inc. (NASDAQ ... - Street Updates - Have a look at Price Moves: OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) , Sage Therapeutics, Inc. (NASDAQ ...Street UpdatesOn 5/6/2016, OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) ended trading session lower at $0.95 with -2.06%. The company traded a volume of 638.74 thousand shares as comparison to average volume of 469.19 thousand shares. During the 52 –week ...
05/08/16 05:42 PMNext Weeks Broker Price Targets For OncoGenex Pharmaceuticals Inc. (OGXI) - Share Trading News - Next Weeks Broker Price Targets For OncoGenex Pharmaceuticals Inc. (OGXI)Share Trading NewsOncoGenex Pharmaceuticals Inc. has a 50 day moving average of 0.84 and a 200 day moving average of 1.17. The stock's market capitalization is 28.31M, it has a 52-week low of 0.46 and a 52-week high of 4.10. The share price of the company (OGXI) was ...
05/07/16 04:57 PMOncogenex Pharmaceuticals Incorporated (NASDAQ:OGXI) Short Interest Decreased By 5.85% - B.O.D.Y Confidential - Oncogenex Pharmaceuticals Incorporated (NASDAQ:OGXI) Short Interest Decreased By 5.85%B.O.D.Y ConfidentialOut of 4 analysts covering OncoGenex Pharma (NASDAQ:OGXI), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. OncoGenex Pharma has been the topic of 6 analyst reports since August 17, 2015 according to StockzIntelligence Inc.and more »
05/05/16 05:49 PMEarnings Outlook on OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) - B.O.D.Y Confidential - Earnings Outlook on OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI)B.O.D.Y ConfidentialAnalysts and investors will be anticipating OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI)'s next earnings release which is expected to be posted on or around 2016-05-12. Sell-side research firms on Wall Street are expecting that the company will post ...and more »

Social

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals logoOncoGenex Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company's segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company's product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell's adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27). OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins-2 and -5 (IGFBP-2, IGFBP-5).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: OGXI
  • CUSIP: 68230A10
Key Metrics:
  • Previous Close: $0.92
  • 50 Day Moving Average: $0.991
  • 200 Day Moving Average: $0.851
  • P/E Ratio: N/A
  • P/E Growth: 0.000
  • Market Cap: $27.55M
  • Beta: 1.87
  • Current Year EPS Consensus Estimate: $-0.83 EPS
  • Next Year EPS Consensus Estimate: $-1.75 EPS
Additional Links:
OncoGenex Pharmaceuticals (NASDAQ:OGXI) Chart for Friday, July, 29, 2016